Caribou Biosciences stock surges after FDA grants RMAT designation to CB-011, its off-the-shelf allogeneic CAR-T for multiple myeloma. Phase 1 data: 92% ORR, 75% complete response in BCMA-naïve patients. More data expected 2026.
Clear Street initiates coverage of Caribou Biosciences with a Buy rating and a $13 price target, highlighting strong CAR-T pipeline potential.
Positive Phase 1 trial data for vispa-cel, an allogeneic (off-the-shelf) CAR-T cell therapy, demonstrates efficacy and durability comparable to traditional autologous treatments, potentially broadening access for patients with large B cell lymphoma.
The FDA is unveiling a faster approval pathway for custom gene-editing therapies, aiming to spark major investment and accelerate cures for rare diseases through Crispr-based innovations.
Intellia Therapeutics halts MAGNITUDE trials of nex-z gene therapy after patient hospitalization with Grade 4 liver toxicity. Over 650 patients enrolled in ATTR amyloidosis studies.
